NRx Pharmaceuticals, Inc. (NRXP)Healthcare | Biotechnology | Wilmington, United States | NasdaqCM
3.55 USD
-0.07
(-1.934%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.51 -0.04 (-0.037%) ⇩ (Aug. 28, 2026, 7:55 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:12 a.m. EDT
This is a distressed biotech play with no income and severe fundamental headwinds. The company is burning cash aggressively, reporting negative operating cash flow and a negative book value, while revenue remains negligible. Although analysts offer lofty price targets based on potential drug approvals, the current reality is a company trading at a fraction of its historical value due to a catastrophic multi-year decline. The options market confirms this pessimism, with traders buying deep out-of-the-money puts to hedge against further collapse. While the recent price action shows a slight bounce off the lows, the lack of a dividend, the massive cash burn, and the precarious balance sheet make this a high-risk speculative vehicle unsuitable for capital preservation. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.097148 |
| AutoARIMA | 0.097148 |
| MSTL | 0.097501 |
| AutoTheta | 0.157876 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.278 |
| Excess Kurtosis | -1.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.112 |
| Market Cap | 153,699,968 |
| Forward P/E | 7.10 |
| Beta | 2.18 |
| Previous Name | NeuroRx, Inc. |
| Website | https://www.nrxpharma.com |
As of Aug. 22, 2026, 4:12 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by massive open interest in out-of-the-money puts relative to calls. The put/call ratio is skewed significantly toward selling, with the bulk of volume concentrated in strikes far above the current price, suggesting a fear of a sharp decline rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.39230764 |
| Address1 | 1,201 N. Market Street |
| Address2 | Suite 111 |
| All Time High | 769.9 |
| All Time Low | 1.1 |
| Ask | 4.54 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 882,480 |
| Average Daily Volume3 Month | 1,150,188 |
| Average Volume | 1,150,188 |
| Average Volume10Days | 882,480 |
| Beta | 2.176 |
| Bid | 3.2 |
| Bid Size | 2 |
| Book Value | -0.004 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.55 |
| Current Ratio | 0.861 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.68 |
| Day Low | 3.5 |
| Display Name | NRx Pharmaceuticals |
| Earnings Call Timestamp End | 1,786,996,800 |
| Earnings Call Timestamp Start | 1,786,996,800 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -19,762,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.463 |
| Enterprise To Revenue | 37.634 |
| Enterprise Value | 127,731,192 |
| Eps Current Year | -0.36 |
| Eps Forward | 0.5 |
| Eps Trailing Twelve Months | -0.5 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.7182 |
| Fifty Day Average Change | -0.16820002 |
| Fifty Day Average Change Percent | -0.04523695 |
| Fifty Two Week Change Percent | 39.230762 |
| Fifty Two Week High | 5.055 |
| Fifty Two Week High Change | -1.5049999 |
| Fifty Two Week High Change Percent | -0.29772502 |
| Fifty Two Week Low | 1.62 |
| Fifty Two Week Low Change | 1.93 |
| Fifty Two Week Low Change Percent | 1.191358 |
| Fifty Two Week Range | 1.62 - 5.055 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,512,397,800,000 |
| Float Shares | 36,425,175 |
| Forward Eps | 0.5 |
| Forward P E | 7.1 |
| Free Cashflow | -9,639,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Fullday Change | -0.0699999 |
| Fullday Change Percent | -1.9337 |
| Fullday Price | 3.513 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.46640998 |
| Gross Profits | 1,583,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06343 |
| Held Percent Institutions | 0.27126 |
| Implied Shares Outstanding | 43,295,767 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,016,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware. |
| Long Name | NRx Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 153,699,968 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_319388181 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -23,480,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 156,730,676 |
| Number Of Analyst Opinions | 4 |
| Open | 3.63 |
| Operating Cashflow | -19,774,000 |
| Operating Margins | -5.90463 |
| Payout Ratio | 0.0 |
| Phone | 484 254 6134 |
| Post Market Change | -0.03699994 |
| Post Market Change Percent | -1.0422518 |
| Post Market Price | 3.513 |
| Post Market Time | 1,787,961,358 |
| Prev Name | NeuroRx, Inc. |
| Previous Close | 3.62 |
| Price Eps Current Year | -9.861111 |
| Price Hint | 4 |
| Price To Book | -887.49994 |
| Price To Sales Trailing12 Months | 45.28579 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.794 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0699999 |
| Regular Market Change Percent | -1.9337 |
| Regular Market Day High | 3.68 |
| Regular Market Day Low | 3.5 |
| Regular Market Day Range | 3.5 - 3.68 |
| Regular Market Open | 3.63 |
| Regular Market Previous Close | 3.62 |
| Regular Market Price | 3.55 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 693,742 |
| Return On Assets | -0.6399 |
| Revenue Per Share | 0.112 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 43,295,767 |
| Shares Percent Shares Out | 0.20030001 |
| Shares Short | 8,673,787 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,198,384 |
| Short Name | NRX Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.20889999 |
| Short Ratio | 7.48 |
| Source Interval | 15 |
| State | DE |
| Symbol | NRXP |
| Target High Price | 49.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 38.25 |
| Target Median Price | 47.0 |
| Total Cash | 26,686,000 |
| Total Cash Per Share | 0.617 |
| Total Debt | 834,000 |
| Total Revenue | 3,394,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.81765 |
| Two Hundred Day Average Change | 0.7323499 |
| Two Hundred Day Average Change Percent | 0.2599151 |
| Type Disp | Equity |
| Volume | 693,742 |
| Website | https://www.nrxpharma.com |
| Zip | 19,801 |